Table 2.
Comparison of clinicopathologic findings of T-NEPC.
| Parameter | Pca-Focal NE (N = 23) | Pca-Diffuse NE (N = 34) | P-value | Pca-NE (N = 57) | NEC (N = 37) | P-value |
|---|---|---|---|---|---|---|
| Age (y) | ||||||
| <65 | 6 (26.1%) | 8 (23.5%) | 0.559 | 16 (28.1%) | 9 (24.3%) | 0.812 |
| ≥65 | 17 (73.9%) | 26 (76.5%) | 41 (71.9%) | 28 (75.7%) | ||
| Metastasis | ||||||
| Negative | 10 (43.5%) | 12 (35.3%) | 0.587 | 22 (38.6%) | 15 (40.5%) | 1.000 |
| Positive | 13 (56.5%) | 22 (64.7%) | 35 (61.4%) | 22 (59.5%) | ||
| AR positivity | ||||||
| Negative | 0 (0%) | 7 (20.6%) | 0.034 | 7 (12.3%) | 22 (59.5%) | 0.000 |
| Positive | 23 (100%) | 27 (79.4%) | 50 (87.7%) | 15 (40.5%) | ||
| PSA positivity | ||||||
| Negative | 6 (26.1%) | 11 (32.4%) | 0.770 | 17 (29.8%) | 28 (75.7%) | 0.000 |
| Positive | 17 (73.9%) | 23 (67.6%) | 40 (70.2%) | 9 (24.3%) | ||
| TNM stage | ||||||
| Stage I–II | 9 (39.1%) | 13 (38.2%) | 1.000 | 22 (38.6%) | 7 (18.9%) | 0.067 |
| Stage III–IV | 14 (60.9%) | 21(61.8%) | 35 (61.4%) | 30 (81.1%) |
Pca, prostate adenocarcinoma; NE, neuroendocrine differentiation; NEC, neuroendocrine cancer
Bold values denote statistical significance at the p < 0.05 level.